Core Viewpoint - The report outlines the continuous supervision and tracking of Jiangsu Haooubo Biopharmaceutical Co., Ltd. by Huatai United Securities, highlighting the company's financial performance, risks, and core competitiveness in the in vitro diagnostic reagent industry. Group 1: Risk Factors - The company faces risks related to new product development and registration, as the in vitro diagnostic reagent industry requires significant time and investment for product approval [1][2]. - There is a risk of core technology leakage and loss of key personnel, which could lead to economic losses for the company [2]. - The company may encounter challenges in expanding new business lines, particularly with the Oduoke series products, which are currently limited to specific regions and require effective marketing efforts [2][3]. - The enzyme-linked immunosorbent assay (ELISA) products may be at risk of being replaced by chemiluminescence products due to the latter's technological advantages [3]. - The food-specific IgG testing products face scrutiny regarding their clinical significance, which could impact sales if regulatory bodies withdraw approval [4]. Group 2: Financial Performance - For the year 2024, the company's operating income was approximately 402.34 million yuan, reflecting a 2.01% increase compared to 2023 [9]. - The net profit attributable to shareholders decreased by 22.24% to approximately 36.80 million yuan, primarily due to increased clinical expenses for the Oduoke product and higher stock incentive costs [10]. - The company's total assets increased by 8.80% to approximately 1.03 billion yuan, while the net assets attributable to shareholders rose by 0.17% [9]. Group 3: Core Competitiveness - The company aims to solidify its market share in the allergy testing field and expand its presence in the autoimmune testing sector through advanced chemiluminescence technology [11]. - With over 300 million allergy patients in China, the allergy testing market presents significant growth potential, and the company has established a comprehensive product menu and scale advantages [11][12]. - The company has developed a nationwide sales and service network, with approximately 700 distributors, enhancing its market reach and brand influence [12]. - Continuous investment in research and development is evident, with R&D expenses amounting to approximately 46.27 million yuan, representing 11.50% of operating income [13].

Group 1 - The core viewpoint of the report is to summarize the sponsorship and regulatory compliance of Jiangsu Haobio Pharmaceutical Co., Ltd. during its initial public offering (IPO) on the Sci-Tech Innovation Board [1] - The issuer, Jiangsu Haobio Pharmaceutical Co., Ltd., has a registered capital of 63.058328 million yuan and was listed on January 13, 2021 [1] - The sponsor, Huatai United Securities Co., Ltd., conducted due diligence and prepared application documents in accordance with relevant laws and regulations [1][3] Group 2 - During the continuous supervision period, the sponsor conducted on-site inspections to check the use of raised funds, project progress, and corporate governance [3][4] - The sponsor identified non-operating fund occupation by related parties and conducted a special on-site inspection, requiring the company to strengthen internal training and governance [3][10] - The sponsor issued 26 verification opinions on the issuer's use of raised funds and related transactions, with no disapproval opinions issued [6][13] Group 3 - The issuer established a special account for raised funds and signed a tripartite supervision agreement with the sponsor and relevant banks [4] - The issuer's actual controller was involved in non-operating fund occupation, leading to internal penalties and a requirement to return the occupied funds [8][11] - The issuer's compliance with information disclosure requirements was affirmed, with no undisclosed matters identified [12][13] Group 4 - The report indicates that the issuer strictly followed regulations regarding the use of raised funds and fulfilled information disclosure obligations accurately [13] - The sponsor will continue to oversee the use of funds for the "New In Vitro Diagnostic Reagent R&D Center Project" until all funds are utilized [13]

Group 1: Company Guarantees - The company provides guarantees for its wholly-owned subsidiaries to enhance overall financing efficiency, aligning with operational needs [1][2] - The total amount of guarantees provided to subsidiaries is RMB 200 million, accounting for 24.63% of the latest audited net assets and 19.36% of total assets [2] Group 2: Fundraising and Usage - The company raised a total of RMB 555.86 million through its initial public offering, with a net amount of RMB 496.47 million after deducting related expenses [5][6] - As of December 31, 2024, the company has strictly adhered to its fundraising management policies, ensuring funds are stored in dedicated accounts and used appropriately [7][8] Group 3: Fund Management and Investment - The company has not used idle fundraising for temporary working capital or to repay bank loans as of December 31, 2024 [9][11] - The company has approved the use of up to RMB 200 million of temporarily idle funds for cash management, ensuring safety and liquidity [9][10] Group 4: Project Updates - The company has decided to conclude certain fundraising projects and extend the timeline for others, specifically the "New In Vitro Diagnostic Reagent R&D Center Project" to September 2025 [12][13] - There are no changes in the use of funds for fundraising projects as of December 31, 2024 [14] Group 5: Compliance and Verification - The company has received positive verification from its accounting firm regarding the management and usage of fundraising, confirming compliance with relevant regulations [16][17]